Poland’s Bioton puts Ukrainian takeover on hold
Polish insulin maker Bioton said on Tuesday it had put on hold its acquisition of Ukrainian firm Indar, after it learnt the Ukrainian state had lost control over the stake it had sought.
Bioton said in a statement that the 70% stake owned by the state was transferred to Gerist Invest Limited, but Ukrainian authorities had taken action to retake control over the firm, which also makes insulin. “The company suspends actions aimed at taking control of Indar until the legal situation of Indar shares is resolved,” Bioton said. In February Bioton CEO Adam Wilczega told Reuters, the company wanted to double its stake at Indar to 60%. (Reuters)
ADVERTISEMENT
MNB Sees Broadening Disinflationary Impact Till Year-end
V4 Agri Officials: WTO Case Over Grain Bans 'Unfortunate'
Lego Invests HUF 54 bln in Expansion in Hungary
Budapest Muni Council Clears Rác Baths Renovation
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
